 | Up a level |
Riether, Carsten; Pabst, Thomas; Höpner, Sabine; Bacher, Ulrike; Hinterbrandner, Magdalena; Banz, Yara; Müller, Rouven; Manz, Markus G.; Gharib, Walid H.; Francisco, David; Bruggmann, Remy; van Rompaey, Luc; Moshir, Mahan; Delahaye, Tim; Gandini, Domenica; Erzeel, Ellen; Hultberg, Anna; Fung, Samson; de Haard, Hans; Leupin, Nicolas; ... (2020). Targeting CD70 with cusatuzumab eliminates acute myeloid leukemia stem cells in patients treated with hypomethylating agents. Nature medicine, 26(9), pp. 1459-1467. Springer Nature 10.1038/s41591-020-0910-8
Jaeger-Ruckstuhl, Carla A.; Hinterbrandner, Magdalena; Höpner, Sabine; Correnti, Colin E; Lüthi, Ursina; Friedli, Olivier; Freigang, Stefan; Al Sayed, Mohamad F; Bührer, Elias D.; Amrein, Michael A.; Schürch, Christian M.; Radpour, Ramin; Riether, Carsten; Ochsenbein, Adrian F. (2020). TNIK signaling imprints CD8+ T cell memory formation early after priming. Nature communications, 11(1), p. 1632. Nature Publishing Group 10.1038/s41467-020-15413-7
Radpour, Ramin; Riether, Carsten; Simillion, Cedric; Höpner, Sabine; Bruggmann, Rémy; Ochsenbein, Adrian (2019). CD8+ T cells expand stem and progenitor cells in favorable but not adverse risk acute myeloid leukemia. Leukemia, 33(10), pp. 2379-2392. Nature Publishing Group 10.1038/s41375-019-0441-9
Riether, Carsten; Schürch, Christian M.; Bührer, Elias D.; Hinterbrandner, Magdalena; Huguenin, Anne-Laure; Höpner, Sabine; Zlobec, Inti; Pabst, Thomas; Radpour, Ramin; Ochsenbein, Adrian F. (2017). CD70/CD27 signaling promotes blast stemness and is a viable therapeutic target in acute myeloid leukemia. The Journal of experimental medicine, 214(2), pp. 359-380. Rockefeller Univ. Press 10.1084/jem.20152008
Riether, Carsten; Pabst, Thomas; Höpner, Sabine; Bacher, Vera; Hinterbrandner, Magdalena; Banz, Yara; Müller, Rouven; Manz, Markus G.; Gharib, Walid H.; Ferreira, David; Bruggmann, Remy; Van Rompaey, Luc; Moshir, Mahan; Delahaye, Tim; Gandini, Domenica; Erzeel, Ellen; Hultberg, Anna; Fung, Samson; De Haard, Hans; Leupin, Nicolas; ... (2 December 2018). 2680 Argx-110 Targeting CD70, in Combination with Azacitidine, Shows Favorable Safety Profile and Promising Anti-Leukemia Activity in Newly Diagnosed AML Patients in an Ongoing Phase 1/2 Clinical Trial (Unpublished). In: ASCO 2018. 2. Dezember 2018.
